{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:52:22Z","timestamp":1774057942235,"version":"3.50.1"},"reference-count":117,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":480,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","award":["10.13039\/100008272"],"award-info":[{"award-number":["10.13039\/100008272"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1093\/annonc\/mdy185","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T19:10:21Z","timestamp":1526497821000},"page":"1509-1520","source":"Crossref","is-referenced-by-count":36,"title":["Advances in the systemic treatment of melanoma brain metastases"],"prefix":"10.1016","volume":"29","author":[{"given":"I.C.","family":"Glitza Oliva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6601-3726","authenticated-orcid":false,"given":"G.","family":"Schvartsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1093\/annonc\/mdy185_bb0015","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jaad.2011.04.032","article-title":"Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992\u20132006","volume":"65","author":"Jemal","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1093\/annonc\/mdy185_bb0020","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PPO.0b013e31824bc981","article-title":"Surgery for distant melanoma metastasis","volume":"18","author":"Leung","year":"2012","journal-title":"Cancer J"},{"issue":"26","key":"10.1093\/annonc\/mdy185_bb0025","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1093\/annonc\/mdy185_bb0035","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1093\/annonc\/mdy185_bb0040","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1093\/annonc\/mdy185_bb0045","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdy185_bb0050","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.4103\/2152-7806.111296","article-title":"Epidemiology and prognosis of brain metastases","volume":"4","author":"Stelzer","year":"2013","journal-title":"Surg Neurol Int"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","article-title":"Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma","volume":"88","author":"Sampson","year":"1998","journal-title":"J Neurosurg"},{"issue":"7","key":"10.1093\/annonc\/mdy185_bb0060","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy185_bb0065","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.4103\/2152-7806.111304","article-title":"Carcinomatous meningitis: leptomeningeal metastases in solid tumors","volume":"4","author":"Le Rhun","year":"2013","journal-title":"Surg Neurol Int"},{"key":"10.1093\/annonc\/mdy185_bb0070","first-page":"1188","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials","volume":"17","author":"Ellingson","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy185_bb0075","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev"},{"issue":"50","key":"10.1093\/annonc\/mdy185_bb0080","doi-asserted-by":"crossref","first-page":"21677","DOI":"10.1073\/pnas.1016234107","article-title":"Malignant cells facilitate lung metastasis by bringing their own soil","volume":"107","author":"Duda","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1093\/annonc\/mdy185_bb0085","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/PPO.0000000000000126","article-title":"The biology of brain metastasis: challenges for therapy","volume":"21","author":"Fidler","year":"2015","journal-title":"Cancer J"},{"issue":"16","key":"10.1093\/annonc\/mdy185_bb0090","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1101\/gad.227502","article-title":"Nr-CAM is a target gene of the beta-catenin\/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis","volume":"16","author":"Conacci-Sorrell","year":"2002","journal-title":"Genes Dev"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/cne.1161","article-title":"Nr-CAM expression in the developing mouse nervous system: ventral midline structures, specific fiber tracts, and neuropilar regions","volume":"434","author":"Lustig","year":"2001","journal-title":"J Comp Neurol"},{"issue":"7249","key":"10.1093\/annonc\/mdy185_bb0100","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nature08021","article-title":"Genes that mediate breast cancer metastasis to the brain","volume":"459","author":"Bos","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1093\/annonc\/mdy185_bb0110","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1158\/1078-0432.CCR-14-0861","article-title":"PLEKHA5 as a biomarker and potential mediator of melanoma brain metastasis","volume":"21","author":"Jilaveanu","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1093\/annonc\/mdy185_bb0115","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nri3391","article-title":"Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates","volume":"13","author":"Shechter","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"Pt 4","key":"10.1093\/annonc\/mdy185_bb0120","first-page":"904","article-title":"Role of connexins in metastatic breast cancer and melanoma brain colonization","volume":"126","author":"Stoletov","year":"2013","journal-title":"J Cell Sci"},{"issue":"5","key":"10.1093\/annonc\/mdy185_bb0125","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/PAT.0b013e328363b3bd","article-title":"Melanoma's connections to the tumour microenvironment","volume":"45","author":"Brandner","year":"2013","journal-title":"Pathology"},{"issue":"2","key":"10.1093\/annonc\/mdy185_bb0130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.canlet.2013.03.005","article-title":"Vascular permeability changes involved in tumor metastasis","volume":"335","author":"Garcia-Roman","year":"2013","journal-title":"Cancer Lett"},{"issue":"6892","key":"10.1093\/annonc\/mdy185_bb0135","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"5","key":"10.1093\/annonc\/mdy185_bb0140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/DAD.0000000000000241","article-title":"Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma","volume":"37","author":"Yaman","year":"2015","journal-title":"Am J Dermatopathol"},{"issue":"20","key":"10.1093\/annonc\/mdy185_bb0145","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1093\/annonc\/mdy185_bb0150","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-13-3003","article-title":"Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target","volume":"20","author":"Chen","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0155","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cam4.50","article-title":"Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases","volume":"2","author":"Niessner","year":"2013","journal-title":"Cancer Med"},{"issue":"7576","key":"10.1093\/annonc\/mdy185_bb0160","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature15376","article-title":"Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth","volume":"527","author":"Zhang","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1093\/annonc\/mdy185_bb0165","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/jpet.112.201475","article-title":"Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases","volume":"344","author":"Mittapalli","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"10.1093\/annonc\/mdy185_bb0170","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1124\/dmd.114.058339","article-title":"Factors influencing the CNS distribution of a novel MEK-1\/2 inhibitor: implications for combination therapy for melanoma brain metastases","volume":"42","author":"Vaidhyanathan","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.112.192195","article-title":"Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)","volume":"342","author":"Mittapalli","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"9829","key":"10.1093\/annonc\/mdy185_bb0180","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1093\/annonc\/mdy185_bb0185","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdy185_bb0190","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdw641","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study","volume":"28","author":"McArthur","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy185_bb0195","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9992","key":"10.1093\/annonc\/mdy185_bb0200","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0205","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0210","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/pcmr.12424","article-title":"Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases","volume":"29","author":"Seifert","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"issue":"4","key":"10.1093\/annonc\/mdy185_bb0215","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1535-7163.MCT-11-0989","article-title":"Combinations of BRAF, MEK, and PI3K\/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations","volume":"11","author":"Greger","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1093\/annonc\/mdy185_bb0220","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.canlet.2011.09.037","article-title":"Dual inhibition of (V600E)BRAF and the PI3K\/AKT\/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism","volume":"314","author":"Sanchez-Hernandez","year":"2012","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0225","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00280-014-2615-5","article-title":"Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma","volume":"75","author":"Tolcher","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1093\/annonc\/mdy185_bb0230","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1158\/1078-0432.CCR-14-1901","article-title":"Antitumor activity in RAS-driven tumors by blocking AKT and MEK","volume":"21","author":"Tolcher","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0235","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/cancers8010017","article-title":"Updates in therapy for advanced melanoma","volume":"8","author":"Singh","year":"2016","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1093\/annonc\/mdy185_bb0240","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1093\/annonc\/mdy185_bb0245","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1093\/annonc\/mdy185_bb0250","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy185_bb0255","first-page":"1199","article-title":"Long-term survival of ipilimumab-naive patients with advanced melanoma treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase 1 trial","volume":"27","author":"Hodi","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"issue":"34","key":"10.1093\/annonc\/mdy185_bb0260","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdy185_bb0270","doi-asserted-by":"crossref","first-page":"603.","DOI":"10.3389\/fimmu.2015.00603","article-title":"T lymphocyte-endothelial interactions: emerging understanding of trafficking and antigen-specific immunity","volume":"6","author":"Carman","year":"2015","journal-title":"Front Immunol"},{"issue":"5","key":"10.1093\/annonc\/mdy185_bb0275","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nrm2889","article-title":"Breaching multiple barriers: leukocyte motility through venular walls and the interstitium","volume":"11","author":"Nourshargh","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"10.1093\/annonc\/mdy185_bb0280","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.it.2012.07.004","article-title":"Capture, crawl, cross: the T cell code to breach the blood\u2013brain barriers","volume":"33","author":"Engelhardt","year":"2012","journal-title":"Trends Immunol"},{"issue":"2","key":"10.1093\/annonc\/mdy185_bb0285","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1084\/jem.20102010","article-title":"CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity","volume":"208","author":"Cruz-Orengo","year":"2011","journal-title":"J Exp Med"},{"issue":"4","key":"10.1093\/annonc\/mdy185_bb0290","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1084\/jem.20051342","article-title":"Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis","volume":"203","author":"Agrawal","year":"2006","journal-title":"J Exp Med"},{"issue":"7560","key":"10.1093\/annonc\/mdy185_bb0295","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1093\/annonc\/mdy185_bb0300","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy185_bb0305","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/annonc\/mdu577","article-title":"Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study","volume":"26","author":"Di Giacomo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdy185_bb0310","unstructured":"ClinicalTrials.gov. A study of fotemustine (FTM) vs FTM and ipilimumab (IPI) or IPI and nivolumab in melanoma brain metastasis (NIBIT-M2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02460068 (18 February 2018, date last accessed)."},{"issue":"7","key":"10.1093\/annonc\/mdy185_bb0315","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy185_bb0320","doi-asserted-by":"crossref","first-page":"abstr 9507","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","article-title":"Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204","volume":"35","author":"Tawbi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy185_bb0325","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy185_bb0330","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","article-title":"Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade","volume":"2","author":"Cooper","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"10.1093\/annonc\/mdy185_bb0335","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"10.1093\/annonc\/mdy185_bb0340","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1093\/annonc\/mdy185_bb0345","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJMc1302338","article-title":"Hepatotoxicity with combination of vemurafenib and ipilimumab","volume":"368","author":"Ribas","year":"2013","journal-title":"N Engl J Med"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdy185_bb0350","first-page":"vi381","article-title":"Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma","volume":"27","author":"Hwu","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdy185_bb0355","unstructured":"ClinicalTrials.gov. Ipilimumab with or without dabrafenib, trametinib, and\/or nivolumab in treating patients with melanoma that is metastatic or cannot be removed by surgery. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01940809 (18 February 2018, date last accessed)."},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy185_bb0360","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/annonc\/mdx377.003","article-title":"KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma","volume":"28","author":"Ribas","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdy185_bb0365","unstructured":"ClinicalTrials.gov. Study of the anti-PD-1 antibody nivolumab in combination with dabrafenib and\/or trametinib in patients with BRAF or NRAS-mutated metastatic melanoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02910700 (18 February 2018, date last accessed)."},{"key":"10.1093\/annonc\/mdy185_bb0370","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. V1.2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf (12 June 2018, date last accessed)."},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0375","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-012-0879-3","article-title":"Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors","volume":"109","author":"Segura","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdy185_bb0380","first-page":"1079","article-title":"Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients","volume":"26","author":"Pape","year":"2012","journal-title":"In Vivo"},{"issue":"6","key":"10.1093\/annonc\/mdy185_bb0385","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/annonc\/mdw134","article-title":"Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma","volume":"27","author":"Geukes Foppen","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdy185_bb0390","first-page":"76","article-title":"Leptomeningeal disease (LMD) from metastatic melanoma: a single institution experience and predictors of survival","volume":"30","author":"Bindal","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1093\/annonc\/mdy185_bb0395","first-page":"399","article-title":"Interleukin-2 and blood brain barrier in cats: pharmacokinetics and tolerance following intrathecal and intravenous administration","volume":"3","author":"Martin","year":"1992","journal-title":"Eur Cytokine Netw"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0400","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00003088-199427010-00003","article-title":"Effects of route and formulation on clinical pharmacokinetics of interleukin-2","volume":"27","author":"Anderson","year":"1994","journal-title":"Clin Pharmacokinet"},{"key":"10.1093\/annonc\/mdy185_bb0405","first-page":"1123","volume":"52","author":"List","year":"1992","journal-title":"Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0410","doi-asserted-by":"crossref","first-page":"e000283","DOI":"10.1136\/esmoopen-2017-000283","article-title":"Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2","volume":"3","author":"Glitza","year":"2018","journal-title":"ESMO Open"},{"issue":"5","key":"10.1093\/annonc\/mdy185_bb0415","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/j.seminoncol.2004.07.013","article-title":"Cognitive sequelae of brain radiation in adults","volume":"31","author":"Laack","year":"2004","journal-title":"Semin Oncol"},{"issue":"14","key":"10.1093\/annonc\/mdy185_bb0420","first-page":"4021","article-title":"Extreme sensitivity of adult neurogenesis to low doses of X-irradiation","volume":"63","author":"Mizumatsu","year":"2003","journal-title":"Cancer Res"},{"issue":"10","key":"10.1093\/annonc\/mdy185_bb0425","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/neuonc\/not114","article-title":"Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Brown","year":"2013","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0430","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1748-717X-7-77","article-title":"Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment","volume":"7","author":"Tallet","year":"2012","journal-title":"Radiat Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdy185_bb0435","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/cncr.26515","article-title":"A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases","volume":"118","author":"Tsao","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdy185_bb0440","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/or.2012.2139","article-title":"Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases","volume":"29","author":"Lwu","year":"2013","journal-title":"Oncol Rep"},{"issue":"3","key":"10.1093\/annonc\/mdy185_bb0445","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3171\/2010.5.JNS1014","article-title":"Outcome predictors of Gamma Knife surgery for melanoma brain metastases","volume":"114","author":"Liew","year":"2011","journal-title":"J Neurosurg"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0450","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11060-015-1881-3","article-title":"Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases","volume":"125","author":"Kohutek","year":"2015","journal-title":"J Neurooncol"},{"issue":"7","key":"10.1093\/annonc\/mdy185_bb0455","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.18632\/oncotarget.6532","article-title":"Analysis of risk and predictors of brain radiation necrosis after radiosurgery","volume":"7","author":"Zhuang","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1093\/annonc\/mdy185_bb0460","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","article-title":"Single-fraction versus multifraction (3 \u00d7 9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis","volume":"95","author":"Minniti","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1093\/annonc\/mdy185_bb0465","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00795-015-0123-2","article-title":"Delayed brain radiation necrosis: pathological review and new molecular targets for treatment","volume":"48","author":"Furuse","year":"2015","journal-title":"Med Mol Morphol"},{"issue":"5","key":"10.1093\/annonc\/mdy185_bb0470","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/COC.0000000000000199","article-title":"Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases","volume":"40","author":"Patel","year":"2017","journal-title":"Am J Clin Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdy185_bb0475","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1016\/j.ejca.2012.05.016","article-title":"Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies","volume":"48","author":"Du Four","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdy185_bb0480","first-page":"1.","article-title":"Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients","volume":"2014","author":"Du Four","year":"2014","journal-title":"Case Rep Oncol Med"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0485","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3171\/2015.6.JNS142763","article-title":"Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?","volume":"125","author":"Colaco","year":"2016","journal-title":"J Neurosurg"},{"issue":"4","key":"10.1093\/annonc\/mdy185_bb0490","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/CMR.0000000000000268","article-title":"BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis","volume":"26","author":"Patel","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdy185_bb0495","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000331191","article-title":"Stereotactic radiosurgery of brain metastasis from melanoma","volume":"25","author":"Marchan","year":"2012","journal-title":"Prog Neurol Surg"},{"key":"10.1093\/annonc\/mdy185_bb0500","unstructured":"ClinicalTrials.gov. Concurrent dabrafenib and trametinib with sterotactic radiation in patients with BRAF mutation-positive malignant melanoma and brain metastases. 2018; https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02974803 (18 February 2018, date last accessed)."},{"issue":"2","key":"10.1093\/annonc\/mdy185_bb0505","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ijrobp.2016.01.038","article-title":"Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the Eastern Cooperative Oncology Group (ECOG)","volume":"95","author":"Anker","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1093\/annonc\/mdy185_bb0510","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","article-title":"Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival","volume":"117","author":"Knisely","year":"2012","journal-title":"J Neurosurg"},{"issue":"6","key":"10.1093\/annonc\/mdy185_bb0515","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cam4.140","article-title":"Ipilimumab and radiation therapy for melanoma brain metastases","volume":"2","author":"Silk","year":"2013","journal-title":"Cancer Med"},{"issue":"1","key":"10.1093\/annonc\/mdy185_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cam4.315","article-title":"Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery","volume":"4","author":"Tazi","year":"2015","journal-title":"Cancer Med"},{"issue":"7","key":"10.1093\/annonc\/mdy185_bb0525","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy185_bb0530","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdy185_bb0535","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-oncology Working Group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy185_bb0540","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy185_bb0545","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"issue":"15","key":"10.1093\/annonc\/mdy185_bb0550","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdy185_bb0555","unstructured":"ClinicalTrials.gov. Phase 2 study of neoadjuvant vemurafenib in melanoma patients with untreated brain metastases. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01781026 (18 February 2018, date last accessed)."},{"issue":"3","key":"10.1093\/annonc\/mdy185_bb0560","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","article-title":"Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study","volume":"50","author":"Dummer","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdy185_bb0565","unstructured":"ClinicalTrials.gov. Interest of the 18F-DOPA-PET imaging in metastatic melanoma treated with B-RAF inhibitors: a pilot study. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02038348 (18 February 2018, date last accessed)."},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdy185_bb0570","first-page":"1156TiP","article-title":"CONVERCE: evaluation of cobimetinib and vemurafenib combination treatment in patients with brain metastases from BRAFV600 mutated melanoma","volume":"27","author":"Lesimple","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdy185_bb0575","unstructured":"ClinicalTrials.gov. Dabrafenib\/trametinib, BRAF or BRAF and MEK pre-op with BRAF and MEK post-op, phase IIB, melanoma with brain mets, biomarkers and metabolites. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01978236 (18 February 2018, date last accessed)."},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy185_bb0580","article-title":"An open-label, uncontrolled, single arm phase II trial of the PI3K inhibitor buparlisib in patients with melanoma brain metastases","volume":"35","author":"Meier","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy185_bb0585","unstructured":"ClinicalTrials.gov. Stereotactic radiation therapy and ipilimumab in treating patients with metastatic melanoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02107755 (18 February 2018, date last accessed)."},{"key":"10.1093\/annonc\/mdy185_bb0590","unstructured":"ClinicalTrials.gov. GEM study: radiation and Yervoy in patients with melanoma and brain metastases (GRAY-B). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02115139 (18 February 2018, date last accessed)."}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419321143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419321143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdy185\/25097344\/mdy185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:40:44Z","timestamp":1624696844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419321143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":117,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0923753419321143"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy185","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}